Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.
Core Innovation
The described invention comprises polymer-conjugated MetAP2 inhibitors, including HPMA-GFLG polymers linked to fumagillol or related inhibitor moieties through chemical and amino-acid linkers. Disclosed embodiments encompass Formula I and Formula II compound classes, including variants below about 60 kDa and self-immolating linkers releasing carbamate derivatives. MetAP2 inhibition and antiangiogenic activity provide the functional basis for treatment applications.
The disclosure reports findings on aqueous stability, thiol reactivity, Cathepsin B-mediated release, tumor-cell assays, and animal tumor models. These conjugates are described as potentially improving efficacy, pharmacokinetic profiles, and activity by weight compared to parent small molecules. The claims specifically recite methods of treating lung cancer, colon cancer, or melanoma by administering effective amounts of Formula I or Formula II compounds.
Claims Coverage
The claim coverage includes two inventive features corresponding to two independent claims directed to methods of treating specified cancers.
Treatment using a formula I compound
A method of treating lung cancer, colon cancer, or melanoma in a subject by administering an effective amount of a Formula I compound or a pharmaceutically acceptable salt thereof, comprising defined polymer, linker, amino-acid, and W components.
Treatment using a formula II compound
A method of treating lung cancer, colon cancer, or melanoma in a subject by administering an effective amount of a Formula II compound or a pharmaceutically acceptable salt thereof, comprising Z-Q-X-Y-C(O)-W with defined polymer attachment, linker, and W components.
Both independent claims cover methods of treating lung cancer, colon cancer, or melanoma using an effective amount of a polymer-linked compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.
Stated Advantages
In the reported in vivo study, polymer conjugates reduced B16-F10 lung metastases relative to saline controls.
In the reported A549 xenograft study, conjugate-treated groups showed slower tumor growth than controls.
The conjugates may improve efficacy, pharmacokinetic profiles, and activity by weight compared to corresponding parent small molecules, potentially allowing lower doses.
Documented Applications
Treatment of lung cancer, colon cancer, or melanoma in a subject using a Formula I or Formula II compound, or a pharmaceutically acceptable salt thereof.
In vitro activity testing against A549 human lung carcinoma cells and HCT-116 human colon tumor cells, and in vivo evaluation in B16-F10 murine melanoma and an A549 xenograft model.
Treatment applications involving solid tumors and other angiogenic or vascular diseases, as well as pharmaceutical compositions and combination therapy.
Interested in licensing this patent?